Business Context and Reporting Period
This Form 8-K Current Report is filed by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc.) for the event date of November 5, 2024. The company is incorporated in Delaware and its common stock (symbol: QLGN) trades on the Nasdaq Capital Market. The filing primarily addresses a corporate action taken to maintain compliance with Nasdaq listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure changes rather than operational financial performance.
Material Changes Versus Prior Period
- Reverse Stock Split: The company effected a one-for-fifty (1:50) reverse stock split of all issued and outstanding common stock effective November 5, 2024, at 12:01 a.m. Eastern Time.
- Share Count Reduction: The number of issued and outstanding shares was reduced from approximately 36,827,020 to approximately 736,431 shares.
- Ownership Interest: The split did not alter any stockholder's percentage ownership interest, except for the rounding of fractional shares.
- Fractional Shares: No fractional shares were issued. Stockholders entitled to fractional shares received cash equal to the fraction multiplied by $5.055 (the closing price on the first business day preceding the effective date).
- Trading Details: The stock began trading on a split-adjusted basis on November 5, 2024. The trading symbol remains "QLGN," and the new CUSIP is 74754R 301.
Guidance, Outlook, and Management Commentary
Purpose of Action: The reverse stock split was intended to bring the company into compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (Nasdaq Listing Rule 5550(a)(2)).
Authorization: The action was authorized by stockholders at the Annual Meeting on October 25, 2024, which approved a proposal allowing a split ratio between 1:10 and 1:50. The Board of Directors selected the 1:50 ratio.
Administrative Details: Equiniti Trust Company acted as the exchange agent. Stockholders holding shares in brokerage accounts ("street name") were not required to take action to effect the exchange.
Important Facts for Investor Verification
- Verify the exact post-split number of outstanding shares, as the filing states this is currently being processed by the transfer agent and is not yet finalized.
- Confirm the receipt of cash payments for fractional shares, calculated at $5.055 per fractional share.
- Monitor the stock price to ensure it remains above the $1.00 minimum bid price requirement following the split.
- Note the change in CUSIP number to 74754R 301 for trading and settlement purposes.
- Review the Certificate of Amendment (Exhibit 3.1) referenced in the filing for the full legal description of the capital structure change.